181 related articles for article (PubMed ID: 37759449)
1. GPER1 Activation Exerts Anti-Tumor Activity in Multiple Myeloma.
Gallo Cantafio ME; Torcasio R; Scionti F; Mesuraca M; Ronchetti D; Pistoni M; Bellizzi D; Passarino G; Morelli E; Neri A; Viglietto G; Amodio N
Cells; 2023 Sep; 12(18):. PubMed ID: 37759449
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma.
Amodio N; Stamato MA; Gullà AM; Morelli E; Romeo E; Raimondi L; Pitari MR; Ferrandino I; Misso G; Caraglia M; Perrotta I; Neri A; Fulciniti M; Rolfo C; Anderson KC; Munshi NC; Tagliaferri P; Tassone P
Mol Cancer Ther; 2016 Jun; 15(6):1364-75. PubMed ID: 27196750
[TBL] [Abstract][Full Text] [Related]
3. miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1.
Amodio N; Di Martino MT; Foresta U; Leone E; Lionetti M; Leotta M; Gullà AM; Pitari MR; Conforti F; Rossi M; Agosti V; Fulciniti M; Misso G; Morabito F; Ferrarini M; Neri A; Caraglia M; Munshi NC; Anderson KC; Tagliaferri P; Tassone P
Cell Death Dis; 2012 Nov; 3(11):e436. PubMed ID: 23190608
[TBL] [Abstract][Full Text] [Related]
4. Lnc NEAT1/miR-29b-3p/Sp1 form a positive feedback loop and modulate bortezomib resistance in human multiple myeloma cells.
Che F; Ye X; Wang Y; Ma S; Wang X
Eur J Pharmacol; 2021 Jan; 891():173752. PubMed ID: 33253679
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia.
Morelli E; Hunter ZR; Fulciniti M; Gullà A; Perrotta ID; Zuccalà V; Federico C; Juli G; Manzoni M; Ronchetti D; Romeo E; Gallo Cantafio ME; Soncini D; Maltese L; Rossi M; Roccaro AM; Cea M; Tassone P; Neri A; Treon SC; Munshi NC; Viglietto G; Amodio N
Exp Hematol Oncol; 2022 Sep; 11(1):54. PubMed ID: 36096954
[TBL] [Abstract][Full Text] [Related]
6. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance.
Kubiczkova L; Kryukov F; Slaby O; Dementyeva E; Jarkovsky J; Nekvindova J; Radova L; Greslikova H; Kuglik P; Vetesnikova E; Pour L; Adam Z; Sevcikova S; Hajek R
Haematologica; 2014 Mar; 99(3):511-8. PubMed ID: 24241494
[TBL] [Abstract][Full Text] [Related]
7. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.
Chiecchio L; Dagrada GP; Ibrahim AH; Dachs Cabanas E; Protheroe RK; Stockley DM; Orchard KH; Cross NC; Harrison CJ; Ross FM;
Haematologica; 2009 Dec; 94(12):1708-13. PubMed ID: 19996118
[TBL] [Abstract][Full Text] [Related]
8. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis.
Pichiorri F; Suh SS; Ladetto M; Kuehl M; Palumbo T; Drandi D; Taccioli C; Zanesi N; Alder H; Hagan JP; Munker R; Volinia S; Boccadoro M; Garzon R; Palumbo A; Aqeilan RI; Croce CM
Proc Natl Acad Sci U S A; 2008 Sep; 105(35):12885-90. PubMed ID: 18728182
[TBL] [Abstract][Full Text] [Related]
9. MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.
Jagannathan S; Vad N; Vallabhapurapu S; Vallabhapurapu S; Anderson KC; Driscoll JJ
Leukemia; 2015 Mar; 29(3):727-38. PubMed ID: 25234165
[TBL] [Abstract][Full Text] [Related]
10. Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease.
Dang M; Wang R; Lee HC; Patel KK; Becnel MR; Han G; Thomas SK; Hao D; Chu Y; Weber DM; Lin P; Lutter-Berka Z; Berrios Nolasco DA; Huang M; Bansal H; Song X; Zhang J; Futreal A; Moreno Rueda LY; Symer DE; Green MR; Rojas Hernandez CM; Kroll M; Afshar-Khargan V; Ndacayisaba LJ; Kuhn P; Neelapu SS; Orlowski RZ; Wang L; Manasanch EE
Cancer Cell; 2023 Jun; 41(6):1032-1047.e4. PubMed ID: 37311413
[TBL] [Abstract][Full Text] [Related]
11. Smoldering multiple myeloma: Reviewing the rationale for intervention.
Gertz M
Leuk Lymphoma; 2022 Sep; 63(9):2033-2040. PubMed ID: 35532298
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
[TBL] [Abstract][Full Text] [Related]
13. CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma.
Yousef S; Kovacsovics-Bankowski M; Salama ME; Bhardwaj N; Steinbach M; Langemo A; Kovacsovics T; Marvin J; Binder M; Panse J; Kröger N; Luetkens T; Atanackovic D
Hum Vaccin Immunother; 2015; 11(7):1606-11. PubMed ID: 26001047
[TBL] [Abstract][Full Text] [Related]
14. The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches.
Lagreca I; Riva G; Nasillo V; Barozzi P; Castelli I; Basso S; Bettelli F; Giusti D; Cuoghi A; Bresciani P; Messerotti A; Gilioli A; Pioli V; Colasante C; Vallerini D; Paolini A; Maccaferri M; Donatelli F; Forghieri F; Morselli M; Colaci E; Leonardi G; Marasca R; Potenza L; Manfredini R; Tagliafico E; Trenti T; Comoli P; Luppi M
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563634
[TBL] [Abstract][Full Text] [Related]
15. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.
Leone E; Morelli E; Di Martino MT; Amodio N; Foresta U; Gullà A; Rossi M; Neri A; Giordano A; Munshi NC; Anderson KC; Tagliaferri P; Tassone P
Clin Cancer Res; 2013 Apr; 19(8):2096-106. PubMed ID: 23446999
[TBL] [Abstract][Full Text] [Related]
16. Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow stroma-mediated drug resistance in multiple myeloma cells.
Abdi J; Rastgoo N; Chen Y; Chen GA; Chang H
BMC Cancer; 2019 Oct; 19(1):975. PubMed ID: 31638931
[TBL] [Abstract][Full Text] [Related]
17. Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma.
Moschetta M; Basile A; Ferrucci A; Frassanito MA; Rao L; Ria R; Solimando AG; Giuliani N; Boccarelli A; Fumarola F; Coluccia M; Rossini B; Ruggieri S; Nico B; Maiorano E; Ribatti D; Roccaro AM; Vacca A
Clin Cancer Res; 2013 Aug; 19(16):4371-82. PubMed ID: 23804425
[TBL] [Abstract][Full Text] [Related]
18. Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma.
Salem DA; Korde N; Venzon DJ; Liewehr DJ; Maric I; Calvo KR; Braylan R; Tembhare PR; Yuan CM; Landgren CO; Stetler-Stevenson M
Leuk Lymphoma; 2018 Jan; 59(1):178-186. PubMed ID: 28540748
[TBL] [Abstract][Full Text] [Related]
19. LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p.
Pan Y; Zhang Y; Liu W; Huang Y; Shen X; Jing R; Pu J; Wang X; Ju S; Cong H; Chen H
Cell Death Dis; 2019 Feb; 10(2):106. PubMed ID: 30728351
[TBL] [Abstract][Full Text] [Related]
20. Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma.
Chen L; Wang S; Zhou Y; Wu X; Entin I; Epstein J; Yaccoby S; Xiong W; Barlogie B; Shaughnessy JD; Zhan F
Blood; 2010 Jan; 115(1):61-70. PubMed ID: 19837979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
